SPP1 promotes the metastasis of liver cancer cells through modulation of the MT1L/vimentin axis.

IF 3.1 3区 医学 Q2 ONCOLOGY
American journal of cancer research Pub Date : 2026-07-15 eCollection Date: 2026-01-01 DOI:10.62347/LALC6308
Jen Yu, Pei-Huan Ho, Chau-Ting Yeh, Ming-Wei Lai, Yang-Hsiang Lin
{"title":"SPP1 promotes the metastasis of liver cancer cells through modulation of the MT1L/vimentin axis.","authors":"Jen Yu, Pei-Huan Ho, Chau-Ting Yeh, Ming-Wei Lai, Yang-Hsiang Lin","doi":"10.62347/LALC6308","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor metastasis, a hallmark of cancer progression including hepatocellular carcinoma (HCC), is closely linked to poor prognosis. Therefore, strategies to suppress tumor metastasis remain an unresolved challenge for improving patient care. We identified that the oncogenic gene secreted phosphoprotein 1 (SPP1) is highly expressed in HCC tissues. A pseudogene-derived long non-coding RNA, metallothionein 1L (MT1L), was found to be negatively regulated by SPP1. Clinically, MT1L expression was reduced in HCC specimens, and its higher expression correlated positively with favorable prognosis. Notably, MT1L expression was inversely correlated with SPP1 expression in HCC. Mechanistically, SPP1 suppressed MT1L expression through the integrin signaling pathway. Overexpression of MT1L inhibited cell motility and lipid accumulation by repressing vimentin expression. Furthermore, rescue experiments demonstrated that MT1L was functionally involved in SPP1-mediated effects. Collectively, our findings reveal a novel association among the SPP1/MT1L/integrin/vimentin axis in HCC progression, suggesting that targeting this pathway may represent a potential therapeutic approach for HCC.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 7","pages":"2985-2996"},"PeriodicalIF":3.1000,"publicationDate":"2026-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13468239/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/LALC6308","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Tumor metastasis, a hallmark of cancer progression including hepatocellular carcinoma (HCC), is closely linked to poor prognosis. Therefore, strategies to suppress tumor metastasis remain an unresolved challenge for improving patient care. We identified that the oncogenic gene secreted phosphoprotein 1 (SPP1) is highly expressed in HCC tissues. A pseudogene-derived long non-coding RNA, metallothionein 1L (MT1L), was found to be negatively regulated by SPP1. Clinically, MT1L expression was reduced in HCC specimens, and its higher expression correlated positively with favorable prognosis. Notably, MT1L expression was inversely correlated with SPP1 expression in HCC. Mechanistically, SPP1 suppressed MT1L expression through the integrin signaling pathway. Overexpression of MT1L inhibited cell motility and lipid accumulation by repressing vimentin expression. Furthermore, rescue experiments demonstrated that MT1L was functionally involved in SPP1-mediated effects. Collectively, our findings reveal a novel association among the SPP1/MT1L/integrin/vimentin axis in HCC progression, suggesting that targeting this pathway may represent a potential therapeutic approach for HCC.

SPP1通过调节MT1L/vimentin轴促进肝癌细胞的转移。
肿瘤转移是包括肝细胞癌(HCC)在内的癌症进展的标志,与不良预后密切相关。因此,抑制肿瘤转移的策略仍然是改善患者护理的一个未解决的挑战。我们发现癌基因分泌磷酸化蛋白1 (SPP1)在HCC组织中高表达。假基因衍生的长链非编码RNA金属硫蛋白1L (metallothionein 1L, MT1L)被SPP1负调控。在临床上,MT1L在HCC标本中的表达降低,其高表达与预后良好呈正相关。值得注意的是,HCC中MT1L的表达与SPP1的表达呈负相关。机制上,SPP1通过整合素信号通路抑制MT1L的表达。过表达MT1L通过抑制vimentin表达来抑制细胞运动和脂质积累。此外,救援实验表明,MT1L在功能上参与了spp1介导的效应。总之,我们的研究结果揭示了SPP1/MT1L/整合素/vimentin轴在HCC进展中的新关联,表明靶向该途径可能代表HCC的潜在治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
3.80%
发文量
263
期刊介绍: The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书